Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
1. Hims & Hers shares dropped 23% after FDA resolved semaglutide shortage. The result directly impacted the compounded drug business. 2. FDA plans enforcement on compounding violations within 60-90 days. This increases regulatory scrutiny on HIMS operations. 3. The company expanded with acquisitions of a peptide facility and Trybe Labs. These deals aim to bolster personalized medication delivery. 4. Weight loss products remain popular with investors despite recent setbacks. Revenue from the program is projected to exceed $100M by 2025.